文献詳細
特集 どこまで変わるの? 腎細胞癌診療の進歩
〈薬物治療〉
文献概要
▶ポイント
・がん免疫サイクルに基づいて免疫チェックポイント阻害薬の作用機序を理解する.
・ニボルマブ+イピリムマブ併用療法は,従来の標準的治療より幅広くかつ持続的な治療効果が期待される.
・ニボルマブ+イピリムマブ併用療法は,単剤療法と比べて高率に重篤な副作用が発現するため,そのリスクマネジメントが重要である.
・がん免疫サイクルに基づいて免疫チェックポイント阻害薬の作用機序を理解する.
・ニボルマブ+イピリムマブ併用療法は,従来の標準的治療より幅広くかつ持続的な治療効果が期待される.
・ニボルマブ+イピリムマブ併用療法は,単剤療法と比べて高率に重篤な副作用が発現するため,そのリスクマネジメントが重要である.
参考文献
1) Motzer RJ, et al : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 : 1803-1813, 2015
2) Motzer RJ, et al : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378 : 1277-1290, 2018
3) Rini BI, et al : Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380 : 1116-1127, 2019
4) Motzer RJ, et al : Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380 : 1103-1115, 2019
5) Choueiri TK, et al : Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384 : 829-841, 2021
6) Motzer R, et al : Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384 : 1289-1300, 2021
7) Chen DS, et al : Oncology Meets Immunology : The Cancer-Immunity Cycle. Immunity 39 : 1-10, 2013
8) Ribas A : Tumor Immunotherapy Directed at PD-1. N Engl J Med 366 : 2517-2519, 2012
T Cell Response. Sci Transl Med 6 : 254ra128, 2014
10) Shi LZ, et al : Interdependent IL-7 and IFN-γ Signalling in T-Cell Controls Tumour Eradication by Combined α-CTLA-4+ α-PD-1 Therapy. Nat Commun 7 : 12335, 2016
11) Kamada T, et al : PD-1 (+) Regulatory T Cells Amplified by PD-1 Blockade Promote Hyperprogression of Cancer. Proc Natl Acad Sci USA 116 : 9999-10008, 2019
12) Heng DY, et al : Prognostic Factors for Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-Targeted Agents : Results from a Large, Multicenter Study. J Clin Oncol 27 : 5794-5799, 2009
13) Motzer RJ, et al : Conditional Survival and Long-Term Efficacy with Nivolumab plus Ipilimumab versus Sunitinib in Patients with Advanced Renal Cell Carcinoma. Cancer 128 : 2085-2097, 2022
14) McGregor BA, et al : Activity of Cabozantinib After Immune Checkpoint Blockade in Metastatic Clear-Cell Renal Cell Carcinoma. Eur J Cancer 135 : 203-210, 2020
15) Méjean A, et al : Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 379 : 417-427, 2018
16) Shirotake S, et al : Impact of Cytoreductive Nephrectomy Following Nivolumab plus Ipilimumab Therapy for Patients with Advanced Renal Cell Carcinoma. Anticancer Res 42 : 2727-2735, 2022
17) Wolchok JD, et al : Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 377 : 1345-1356, 2017
18) Motzer RJ, et al : Survival Outcomes and Independent Response Assessment with Nivolumab plus Ipilimumab versus Sunitinib in Patients with Advanced Renal Cell Carcinoma : 42-Month Follow-Up of a Randomized Phase 3 Clinical Trial. J Immunother Cancer 8 : e000891, 2020
19) Wang DY, et al : Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors : A Systematic Review and Meta-analysis. JAMA Oncol 4 : 1721-1728, 2018
掲載誌情報